Metoclopramide

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human tablet has sourced current registrations in Georgia and EU/EEA, an identifiable manufacturer, strength and half-tablet split. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The tablet can be split only to 5 mg. That can match selected medium or large dogs, but small dogs and dose adjustment commonly require a lower strength or validated compound; repeated q8h home administration and variable oral exposure add burden.

The exact human tablet has sourced current registrations in Georgia and EU/EEA, an identifiable manufacturer, strength and half-tablet split. It has no veterinary authorisation, no checked UK or US exact trade-name registration, and animal use is off-label.

A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The smallest verified half-tablet is 5 mg, above the usual calculated dose for a typical cat. Crushing does not make informal powder division accurate or validated, so most cats require a lower-strength liquid or pharmacy-prepared patient-specific dose.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.

The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label.

A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome.

Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review.

The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use.